Tags

Type your tag names separated by a space and hit enter

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Curr Med Res Opin. 2007 Feb; 23(2):245-50.CM

Abstract

OBJECTIVE

This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder.

METHODS

In this multicenter trial, depressed patients (DSM-IV defined; baseline Montgomery-Asberg Depression Rating Scale [MADRS] 22) aged 18-80 years were randomly assigned to 8 weeks of double-blind treatment with escitalopram (10 mg/day) or sertraline (50-200 mg/day) following a 1-week single-blind placebo lead-in period. There was no placebo comparison arm. Sertraline was initiated at 50 mg/day, and could be increased by 50 mg/day at weekly intervals based on clinical need and tolerability at the lower dose level. The blind was maintained with matching double-blind placebo capsules for the escitalopram group. Change from baseline to endpoint in MADRS total score (last observation carried forward) was the primary efficacy measure.

RESULTS

A total of 212 patients received double-blind medication. At week 8, the mean sertraline dosage was 144 mg/day (median = 150 mg/day). Mean changes from baseline to endpoint in MADRS scores were -19.1 and -18.4 for the escitalopram and sertraline groups, respectively. At endpoint, 75% and 70% of escitalopram- and sertraline-treated patients, respectively, were responders (> or =50% improvement from baseline in mean MADRS scores). Both treatments were generally well tolerated; only 2% and 4% of patients prematurely discontinued escitalopram and sertraline treatment, respectively, due to adverse events.

CONCLUSION

No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50-200 mg/day. At these doses, both escitalopram and sertraline were generally well tolerated.

Authors+Show Affiliations

Forest Research Institute, Jersey City, NJ 07311, USA. Daniel.Ventura@frx.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17288677

Citation

Ventura, Daniel, et al. "Escitalopram Versus Sertraline in the Treatment of Major Depressive Disorder: a Randomized Clinical Trial." Current Medical Research and Opinion, vol. 23, no. 2, 2007, pp. 245-50.
Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin. 2007;23(2):245-50.
Ventura, D., Armstrong, E. P., Skrepnek, G. H., & Haim Erder, M. (2007). Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current Medical Research and Opinion, 23(2), 245-50.
Ventura D, et al. Escitalopram Versus Sertraline in the Treatment of Major Depressive Disorder: a Randomized Clinical Trial. Curr Med Res Opin. 2007;23(2):245-50. PubMed PMID: 17288677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. AU - Ventura,Daniel, AU - Armstrong,Edward P, AU - Skrepnek,Grant H, AU - Haim Erder,M, PY - 2007/2/10/pubmed PY - 2007/3/16/medline PY - 2007/2/10/entrez SP - 245 EP - 50 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 23 IS - 2 N2 - OBJECTIVE: This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder. METHODS: In this multicenter trial, depressed patients (DSM-IV defined; baseline Montgomery-Asberg Depression Rating Scale [MADRS] 22) aged 18-80 years were randomly assigned to 8 weeks of double-blind treatment with escitalopram (10 mg/day) or sertraline (50-200 mg/day) following a 1-week single-blind placebo lead-in period. There was no placebo comparison arm. Sertraline was initiated at 50 mg/day, and could be increased by 50 mg/day at weekly intervals based on clinical need and tolerability at the lower dose level. The blind was maintained with matching double-blind placebo capsules for the escitalopram group. Change from baseline to endpoint in MADRS total score (last observation carried forward) was the primary efficacy measure. RESULTS: A total of 212 patients received double-blind medication. At week 8, the mean sertraline dosage was 144 mg/day (median = 150 mg/day). Mean changes from baseline to endpoint in MADRS scores were -19.1 and -18.4 for the escitalopram and sertraline groups, respectively. At endpoint, 75% and 70% of escitalopram- and sertraline-treated patients, respectively, were responders (> or =50% improvement from baseline in mean MADRS scores). Both treatments were generally well tolerated; only 2% and 4% of patients prematurely discontinued escitalopram and sertraline treatment, respectively, due to adverse events. CONCLUSION: No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50-200 mg/day. At these doses, both escitalopram and sertraline were generally well tolerated. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17288677/Escitalopram_versus_sertraline_in_the_treatment_of_major_depressive_disorder:_a_randomized_clinical_trial_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X167273 DB - PRIME DP - Unbound Medicine ER -